EverBridge Group and Beijing Guanqiao medical form strategic partnership to advance pulmonary vascular intervention technology

On September 4, 2024, the strategic cooperation meeting between EverBridge Group and Beijing Guanqiao Medical Technology Co., Ltd. was successfully held in Shanghai, marking the beginning of a new chapter in their collaboration in the field of pulmonary vascular intervention.

This partnership between EverBridge Group and Guanqiao Medical focuses on pulmonary artery balloon products and their supporting access devices, specifically designed for the interventional Treatment of chronic thromboembolic pulmonary hypertension (CTEPH). These products successfully address a gap in the market, providing innovative, safe, and effective Treatment options for more patients.

Starting from September 2024, EverBridge Group will take full responsibility for the commercialization and implementation of pulmonary artery balloon products in Greater China. During the strategic cooperation meeting, senior leaders from both companies engaged in in-depth discussions on channel policies, market promotion strategies, and professional technical training. Both parties expressed their commitment to integrating resources and technologies, leveraging their respective strengths to jointly advance the R&D innovation and market promotion of pulmonary artery balloon products, opening new avenues for CTEPH Treatment. Sales representatives and commercial partners from both sides witnessed this significant moment.

Looking ahead, EverBridge Group and Guanqiao Medical will dedicate themselves to deepening their efforts in the field of pulmonary vascular intervention, working together to provide more diverse and high-quality Treatment options for CTEPH patients, thereby improving their quality of life. By pooling their wisdom and resources, the two companies aim to promote the widespread application of pulmonary balloon products in Greater China. Through the popularization of this innovative medical product, they hope to create more miracles in the medical field, bringing hope, well-being, and health to countless patients.

About Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe pulmonary vascular disease in which patients develop pulmonary hypertension due to blood clots in the pulmonary arteries, subsequently affecting cardiopulmonary function. Currently, the Treatment of CTEPH primarily relies on medication, surgery, and interventional therapy. As an innovative interventional Treatment, pulmonary balloon products work by deploying a balloon in the obstructed pulmonary artery to clear the blockage, thereby improving blood flow, reducing pulmonary artery pressure, and alleviating patient symptoms.